Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response

Shengshan Xu(Jiangmen Central Hospital), Zhuming Lu(Jiangmen Central Hospital), Youbin Zheng(Jiangmen Wuyi Traditional Chinese Medicine Hospital), Min Ye(Jiangmen Central Hospital), Dongxi Zhang(Jiangmen Central Hospital), Zumei Li(Jiangmen Central Hospital), Tao Shen(Jiangmen Central Hospital)
BMC Cancer
August 28, 2024
10.1186/s12885-024-12843-0
Cited by 50

Related Papers

The Role of PLIN3 in Prognosis and Tumor-Associated Macrophage Infiltration: A Pan-Cancer Analysis
|Journal of Inflammation Research|2025|48
Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer
|Frontiers in Immunology|2024|45
Construction and validation of a hypoxia-related gene signature to predict the prognosis of breast cancer
|BMC Cancer|2024|43
Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses
|BMC Cancer|2025|41
Multi‑omics identification of a signature based on malignant cell-associated ligand–receptor genes for lung adenocarcinoma
|BMC Cancer|2024|36